Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene’s Phase III Data Shows PD-1 Effective as First Line Therapy for Esophageal Carcinoma

publication date: Jun 30, 2022

Beijing’s BeiGene announced positive results from a global Phase III trial of its PD-1 plus chemotherapy as a therapy for esophageal squamous cell carcinoma (ESCC). Tislelizumab plus chemotherapy increased overall survival to 17.2 months against 10.6 months for chemotherapy alone. The Phase III trial tested tislelizumab as a first-line therapy in patients with advanced or metastatic ESCC. The PD-1 is already approved as a second line ESCC treatment in China. In early 2021, BeiGene out-licensed ex-China rights for the PD-1 to Novartis in a $2.2 billion agreement. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022